APPLICATION
NDA020090
TYPE
NDA
ORIGINAL APPROVAL
1993-12-23
LATEST ACTION
2024-02-12
ROUTE
ORAL
DOSAGE FORM
FOR SUSPENSION
MARKETING STATUS
Prescription
Products
DIFLUCAN · ReferencePrescription
FLUCONAZOLE 50MG/5ML · FOR SUSPENSION · ORAL
DIFLUCAN · ReferencePrescription
FLUCONAZOLE 200MG/5ML · FOR SUSPENSION · ORAL
Approval history
2014-07-28Manufacturing (CMC) · Supplement 43AP
2014-01-07Manufacturing (CMC) · Supplement 41AP
2001-03-05Manufacturing (CMC) · Supplement 13AP
1999-02-22Labeling · Supplement 11 · standardAP
1997-08-05Labeling · Supplement 10 · standardAP
1997-02-19Labeling · Supplement 9 · standardAP
1996-08-06Labeling · Supplement 8 · standardAP
1996-07-23Labeling · Supplement 6 · standardAP
1995-12-22Manufacturing (CMC) · Supplement 5AP
1995-02-21Labeling · Supplement 3 · standardAP
1995-02-21Labeling · Supplement 4 · standardAP
1994-06-30Labeling · Supplement 2 · standardAP
1994-03-22Labeling · Supplement 1 · standardAP
1993-12-23Type 3 - New Dosage Form · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.